[1] European Association for the Study of the Liver. Electronic address eee. Easl clinical practice guidelines: Vascular diseases of the liver. J Hepatol, 2016, 64(1): 179-202.
[2] Zu M, Xu H, Zhang Q, et al. Review of Budd-Chiari syndrome. J Interv Med, 2020, 3(2): 65-76.
[3] Parker RG. Occlusion of the hepatic veins in man. Medicine (Baltimore), 1959, 38: 369-402.
[4] 罗文萍, 马红, 赵新颜. 肝血管病的病理学特征及鉴别诊断要点. 临床肝胆病杂志, 2018, 34(11): 6.
[5] Li Y, De Stefano V, Li H, et al. Epidemiology of Budd-Chiari syndrome: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol, 2019, 43(4): 468-474.
[6] Qi X, Han G, Guo X, et al. The aetiology of primary Budd-Chiari syndrome-differences between the west and China. Aliment Pharmacol Ther, 2016, 44(11-12): 1152-1167.
[7] Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med, 2009, 151 (3): 167-175.
[8] Westbrook RH, Lea NC, Mohamedali AM, et al. Prevalence and clinical outcomes of the 46/1 haplotype, janus kinase 2 mutations, and ten-eleven translocation 2 mutations in budd-chiari syndrome and their impact on thrombotic complications post liver transplantation. Liver Transpl, 2012, 18(7): 819- 827.
[9] Garcia-Pagan JC, Heydtmann M, Raffa S, et al. Tips for Budd-Chiari syndrome: Long-term results and prognostics factors in 124 patients. Gastroenterology, 2008, 135(3): 808-815.
[10] Qi X, Yang Z, De Stefano V, et al. Methylenetetrahydrofolate reductase c677t gene mutation and hyperhomocysteinemia in budd-chiari syndrome and portal vein thrombosis: A systematic review and meta-analysis of observational studies. Hepatol Res, 2014, 44(14): E480-498.
[11] Qi X, De Stefano V, Wang J, et al. Prevalence of inherited antithrombin, protein c, and protein s deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: A systematic review and meta-analysis of observational studies. J Gastroenterol Hepatol, 2013, 28(3): 432-442.
[12] 中国研究型医院学会布-加综合征及肝脏血管病专业委员会. 中国巴德-吉亚利综合征多学科协作诊治专家共识(2021版). 中华外科杂志, 2022, 60(4): 8.
[13] 中国医师协会腔内血管学专业委员会腔静脉阻塞专家委员会. 下腔静脉与肝静脉"膜"与"节段"阻塞界定的专家共识. 介入放射学杂志, 2016, 25(7): 559-561.
[14] 中国医师协会腔内血管学专业委员会腔静脉阻塞专家委员会. 布-加综合征亚型分型的专家共识. 介入放射学杂志, 2017, 26(3): 7.
[15] Hoffmann T, Voigtlander H, Frohlich E, et al. Single-center study: Evaluation of sonography in Budd-Chiari syndrome. Z Gastroenterol, 2022, 60(7): 1111-1117.
[16] Shukla A, Shreshtha A, Mukund A, et al. Budd-Chiari syndrome: Consensus guidance of the Asian pacific association for the study of the liver (apasl). Hepatol Int, 2021, 15(3): 531-567.
[17] Liu SY, Xiao P, Cao HC, et al. Accuracy of computed tomographic angiography in the diagnosis of patients with inferior vena cava partial obstruction in Budd-Chiari syndrome. J Gastroenterol Hepatol, 2016, 31(12): 1933-1939.
[18] Gupta P, Bansal V, Kumar MP, et al. Diagnostic accuracy of doppler ultrasound, CT and MRI in Budd-Chiari syndrome: Systematic review and meta-analysis. Br J Radiol, 2020, 93(1109): 20190847.
[19] Simonetto DA, Singal AK, Garcia-Tsao G, et al. Acg clinical guideline: Disorders of the hepatic and mesenteric circulation. Am J Gastroenterol, 2020, 115(1): 18-40.
[20] Li Z, Wang L, Yi F, et al. Rapid development of gingival bleeding after rivaroxaban in a patient with budd-chiari syndrome. Liver Int, 2021, 41(9): 2236-2237.
[21] 中国微循环学会门脉高压专家委员会. 布-加综合征外科治疗规范的专家共识. 血管与腔内血管外科杂志, 2020, 24(6): 11. |
